Larazotide Acetate

Larazotide is a synthetic analogue of a Vibrio cholerae zonula occludens toxin fragment. Applied luminally it blocks zonulin-driven signalling at the apical enterocyte surface, preventing actin cytoskeleton rearrangement and the redistribution of occludin and ZO-1 that opens the paracellular space. The practical consequence is reduced translocation of gliadin peptides and other antigens across the epithelium. It is essentially non-absorbed, so all of its activity is local to the gut lumen — a genuinely elegant design that unfortunately did not translate into a significant symptom benefit in coeliac disease at phase 3.

Targets: Zonulin pathway, Tight junction proteins ZO-1 and occludin, Actin cytoskeleton in enterocytes

• · 0.5 mg three times daily was the dose that outperformed in phase 2b and was carried into phase 3. Curiously, higher doses (1 mg and 2 mg) performed worse, which is one of the reasons the programme is viewed sceptically.

Work out your exact syringe units →

• commonHeadache— The most frequently reported event in trials, and close to placebo rate.
• commonNasopharyngitis and upper respiratory symptoms— Also close to placebo rate.
• uncommonNausea, flatulence, abdominal discomfort— Generally indistinguishable from placebo.
• uncommonUrinary tract infection— Reported in the phase 2 programme.

• Not a substitute for a gluten-free diet in coeliac disease — the phase 3 failure means it cannot be relied on to protect against a gluten exposure.

• synergybpc-157-gut — Theoretically complementary — one seals the junctions, the other repairs the mucosa — but no combination data exist.

• · In coeliac disease, tissue transglutaminase antibodies and symptom diaries remain the meaningful endpoints.
• · Lactulose/mannitol or confocal permeability testing if you actually want to know whether it is doing anything.

Not approved in any jurisdiction. Development for coeliac disease was discontinued by 9 Meters Biopharma in 2022; grey-market supply exists as a research chemical.

• Leffler et al. 2015, larazotide acetate phase 2b in coeliac disease, Gastroenterology (trial)
• 9 Meters Biopharma interim analysis announcement, phase 3 CeDLara discontinuation, June 2022 (trial)
• Fasano, zonulin and regulation of intestinal barrier function (review)

Larazotide is derived from a fragment of the Vibrio cholerae zonula occludens toxin, the molecule that gave zonulin its name. Zonulin binds an apical enterocyte receptor and triggers PAR2 and EGFR-linked signalling that phosphorylates ZO-1 and occludin, releasing them from the tight junction and allowing actomyosin contraction to pull the junction open. That is the physiological mechanism by which the gut deliberately increases paracellular permeability, and it is hijacked by gliadin in coeliac disease. Larazotide occupies that pathway without triggering it, so the actin rearrangement does not happen, ZO-1 and occludin stay where they are, and the paracellular space does not widen. Practically, less gliadin peptide crosses, less reaches the lamina propria, and less transglutaminase-mediated deamidation and T-cell activation follows. The design is genuinely elegant. The clinical result is the interesting part, and the part most 'leaky gut' marketing omits. In the phase 2b trial the 0.5 mg dose beat placebo on symptoms while 1 mg and 2 mg did not. An inverted dose-response like that is either real bell-shaped pharmacology — plausible if higher concentrations allow the peptide to self-associate or act as a partial agonist — or it is a chance finding in a multi-arm trial. The phase 3 that would have distinguished those two explanations was terminated at interim analysis. So the honest reading is that the mechanism is well demonstrated at the level of tight-junction biology and the clinical benefit was never established.

The characteristic failure is conceptual. Larazotide gets sold in the wellness market as a leaky-gut cure, and it is the only compound in that entire category that was actually put through a properly powered phase 3 — where it did not work. People buying grey-market larazotide today are buying a drug whose developer discontinued it, which is a strange position to be in. The second failure is dose escalation. Everyone's instinct on a peptide that is not working is to take more. With this molecule more was tested and was worse. If 0.5 mg three times daily is not helping after six weeks, 2 mg will not. The third is timing. It has to be in place before the antigen arrives. Taken after a meal, or taken once a day, it is not doing the thing it was designed to do. Three doses a day, fifteen minutes ahead of food, or do not bother. The fourth is that anything sold as injectable larazotide is being sold by someone who does not understand the drug. It is a luminally acting, deliberately non-absorbed peptide. Injecting it bypasses the only compartment where it works.

1. 500 mcgFrom day one — 0.5 mg taken about 15 minutes before each of the three main meals. There is no titration and there should not be one. This is the only dose that ever beat placebo.
2. 1 mgTested and failed — 1 mg three times daily was tested in phase 2b and did not separate from placebo. Listed here only so you understand that going up is going backwards with this molecule.
3. 2 mgTested and failed — 2 mg three times daily also failed to beat placebo. The dose-response is inverted. Anyone advising you to escalate larazotide has not read the trial.

• Zonulin pathway at the apical enterocyte surface — No binding constant published. The zonulin receptor itself has never been definitively cloned and identified, which is a real gap — larazotide is an antagonist of a pathway whose receptor is not molecularly defined.

  Prevents zonulin-triggered tight-junction disassembly. Downstream this preserves ZO-1 and occludin localisation and blocks the actomyosin contraction that opens the paracellular space.

• PAR2 / EGFR transactivation (zonulin's proposed signalling route) — Not directly measured for larazotide.

  Indirectly blunted, as the upstream trigger is prevented. Larazotide is not a PAR2 antagonist in its own right.

• Perijunctional actomyosin ring — Not a receptor.

  Prevents the contraction that mechanically opens the junction. This is the observable endpoint in the cell-culture and biopsy work.

• NCT01396213 — Larazotide acetate for persistent symptoms of coeliac disease despite a gluten-free diet (Leffler et al.) Phase 2b · n=342 · 12 weeks · 2015

  Difference in average on-treatment Coeliac Disease Gastrointestinal Symptom Rating Scale score, over 12 weeks of treatment bracketed by 4-week placebo run-in and run-out. The 0.5 mg three-times-daily arm met the endpoint (P = .022) with a 26% decrease in symptomatic days; the 1 mg and 2 mg arms did not separate from placebo.

• NCT03569007 — CeDLara, study of larazotide acetate for relief of coeliac disease symptoms Phase 3 · n=307 · 2022

  Relief of coeliac disease symptoms in patients on a gluten-free diet. ClinicalTrials.gov records the study as Terminated, with the reason given as 'Trial terminated by Sponsor', following an interim analysis indicating the effect size would not reach significance.

• NCT00620451 — Randomised, double-blind, placebo-controlled study of larazotide acetate in active coeliac disease Phase 2 · n=105

  Efficacy and safety of larazotide acetate in subjects with active coeliac disease. Completed.

• NCT00362856 — Safety and tolerability of larazotide acetate in coeliac disease subjects Phase 2 · n=80

  Safety and tolerability of larazotide acetate. Completed.

The tight-junction effect is immediate and meal-locked — present while the peptide is in contact with the epithelium, gone once it has passed. There is no loading period and no accumulation. Symptom endpoints in the trials were assessed over 12 weeks, and the phase 2b signal was a modest reduction in symptomatic days rather than a step change. If you are going to trial it, give it six weeks with a lactulose/mannitol ratio at each end so you get a mechanistic answer rather than a mood.

There is a theoretically clean pairing with BPC-157 — one prevents the junction opening, the other is claimed to repair the mucosa behind it — and precisely zero combination data. If you run both, run larazotide meal-locked and BPC-157 on an empty stomach so they are not competing for the same luminal window. The pairing that makes more practical sense is larazotide with a genuinely strict gluten-free diet in coeliac disease, and that is exactly the population where the phase 3 failed. Understand what that means: it did not fail against no diet, it failed as an add-on in people who still had symptoms despite the diet. Adding it to a diet you are already breaking is the worst possible use case. Do not stack it with glutenase enzyme products and treat the combination as permission to eat gluten. Neither has shown it can protect against a real exposure.

Larazotide is the honest benchmark for the whole intestinal permeability category, and it is the reason to be sceptical of everything else in it. It had a clean mechanism, a specific target, an elegant non-absorbed design, real phase 2b evidence, and a well-funded phase 3 — and the phase 3 was stopped for futility. Every supplement and peptide marketed for leaky gut is claiming to do what larazotide did, with less evidence than larazotide had when it failed. Against BPC-157, larazotide is the more rigorously tested compound and the narrower one: it prevents a specific pathological process rather than promoting repair. Against colostrum, colostrum has smaller trials but positive ones on the same permeability endpoint. If your goal is specifically to reduce a measured lactulose/mannitol ratio, colostrum has the better human record; if your goal is coeliac symptom control on a gluten-free diet, larazotide has the better mechanism and a negative phase 3.

There is no legitimate commercial product, so there is no real price. Grey-market supply exists at widely varying and largely arbitrary prices. I did not verify a current figure and would not trust one — a discontinued phase 3 peptide with no reference standard is exactly the market where mislabelled material circulates.

• ?The zonulin receptor has never been definitively identified at a molecular level, so 'zonulin antagonist' describes a functional effect rather than a defined receptor interaction.
• ?Whether the inverted dose-response in phase 2b is real pharmacology or a multiple-comparison artefact was never resolved, because the phase 3 that would have answered it was terminated early.
• ?I verified that CeDLara (NCT03569007) was terminated by the sponsor with 307 enrolled, but ClinicalTrials.gov gives no efficacy results and I did not locate a published interim analysis.
• ?No formal human PK study of larazotide surfaced in this session; the non-absorption claim rests on the design and on statements in the trial literature rather than a PK paper I resolved.
• ?NCT00620451 and NCT00362856 were verified as existing and completed on ClinicalTrials.gov; I did not verify their published results, and no year is asserted for them.

• Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial Leffler DA, Kelly CP, Green PH, et al., Gastroenterology, 2015 · PMID 25683116

  The phase 2b trial. This is the paper containing the inverted dose-response — 0.5 mg worked, 1 mg and 2 mg did not — and it is the single most important thing to read before dosing this compound.

• Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer Fasano A, Physiological Reviews, 2011 · PMID 21248165

  The foundational zonulin review, from the laboratory that discovered zonulin and developed larazotide. Read it as the strongest version of the argument rather than a neutral one.

• Zonulin, regulation of tight junctions, and autoimmune diseases Fasano A, Annals of the New York Academy of Sciences, 2012 · PMID 22731712

  Shorter companion piece covering the tight-junction mechanism larazotide targets.

• PubChem CID 9810532 — larazotide, C32H55N9O10, MW 725.8, CAS 258818-34-7 PubChem, National Library of Medicine

  Sequence and molecular weight verification: H-Gly-Gly-Val-Leu-Val-Gln-Pro-Gly-OH, 725.8 Da.